Primary Outcomes
Measure: Serum Concentration of interleukin-6 (IL-6) Following Administration of 8 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of 8 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of Ferritin Following Administration of 8 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of C-reactive Protein (CRP) Following Administration of 8 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of IL-6 Following Administration of 4 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of sIL-6R Following Administration of 4 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of Ferritin Following Administration of 4 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Measure: Serum Concentration of CRP Following Administration of 4 mg/kg IV TCZ Time: At pre-defined intervals from first TCZ administration to Day 28
Secondary Outcomes
Measure: Pecentage of Participants with Adverse Events Time: Up to Day 28
Measure: Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time Time: Up to Day 28
Measure: Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity Time: Up to Day 28
Measure: Proportion of Participants with any Post-Treatment Infection Time: Up to Day 28